Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach
Rune Viig Overgaard, Oscar Birkhan, Naveen Rathor, Thomas Sparsø et autres
4 citationsDiabetes Obesity and Metabolism